Abstract: Products and methods for modifying apolipoprotein B mRNA editing in vivo, reducing serum LDL levels, and treating or preventing an atherogenic disease or disorder are disclosed. Such methods involve the use of a protein including APOBEC-1 or fragments thereof which can edit mRNA encoding apolipoprotein B. The protein including APOBEC-1 can be taken up by cells in the form of a delivery vehicle, such as a liposome or niosome, or directly as a chimeric protein which includes a first polypeptide that includes a protein transduction domain and a second polypeptide that includes APOBEC-1 or a fragment thereof which can edit mRNA encoding apolipoprotein B.

Abstract: Disclosed are compositions for chimeric proteins comprising a protein transduction domain and a deaminase domain, mimetics or analog thereof, and uses of same.

Abstract: Methods for use in mobilizing triacylglycerol (TAG) in order to elevate apoliprotein B and Very-Low-Density Lipoprotein (VLDL) are described. In some embodiments, the method involves providing betaine in an amount of about 3 gm/kg of body weight per day in order to mobilize TAG. In some embodiments, serum VLDL is elevated as a result of mobilizing hepatic TAG. In some embodiments, the method includes restricting methionine intake to less than about 1 gm/kg of body weight per day. In some embodiments, the method includes feeding L-cysteine at a level of at least about 3 gm/kg of body weight per day. In some embodiments, the method includes feeding choline bitartrate at a level of about 1.25 gm/kg of body weight per day. Mobilizing hepatic TAG is effective to reduce hepatic steatosis.

Abstract: Products and methods for modifying apolipoprotein B mRNA editing in vivo, reducing serum LDL levels, and treating or preventing an atherogenic disease or disorder are disclosed. Such methods involve the use of a protein including APOBEC-1 or fragments thereof which can edit mRNA encoding apolipoprotein B. The protein including APOBEC-1 can be taken up by cells in the form of a delivery vehicle, such as a liposome or noisome, or directly as a chimeric protein which includes a first polypeptide that includes a protein transduction domain and a second polypeptide that includes APOBEC-1 or a fragment thereof which can edit mRNA encoding apolipoprotein B.